1. Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, Goedee HS, Harbo T, Kuwabara S, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Sommer C, Topaloglu HA. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 Sep; 26 (3): 242 - 268. doi: 10.1111/jns.12455. Epub 2021 Jul 30. PMID: 34085743.

2. Nevo Y, Pestronk A, Kornberg A.J, Connolly A.M, Yee W.C, Iqbal I, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996; 47: 98 - 102. https://doi.org/10.1212/wnl.47.1.98

3. Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscul Disord. 2000; 10: 398 - 406. https://doi.org/10.1016/s0960-8966(00)00119-x

4. Rossignol E, D"Anjou G, Lapointe N, Haddad E, Vanasse M. Evolution and treatment of childhood chronic inflammatory polyneuropathy. Pediatr Neurol. (2007) 36: 88 - 94. https://doi.org/10.1016/j.pediatrneurol.2006.09.012

5. Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. (2010) 41: 202 - 7. https://doi.org/10.1002/mus.21480

6. Dalakas MC, Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7: 507. https://doi.org/10.1038/nrneurol.2011.121

7. Schneider-Hohendorf T, Schwab N, N, et al. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78: 402. DOI 10.1212/WNL.0b013e318245d250

8. Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin Neurol 2012; 32: 187. https://doi.org/10.1055/s-0032-1329194

9. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015; 86: 973. https://doi.org/10.1136/jnnp-2014-309697

10. Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621 PMID: 1186294.

11. Harbo T, Andersen H, Jakobsen J. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2008; 38: 1036. https://doi.org/10.1002/mus.21000

12. Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology 2019; 52: 161. doi: 10.1159/000494291.

13. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014; 21 (1): 28 - 33. https://doi.org/10.1111/ene.12190

14. Iijima M, Koike H, Hattori N, et al. Refractory Peripheral Neuropathy Study Group of Japan. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry. 2008; 79 (9): 1040 - 1043. https://doi.org/10.1136/jnnp.2007.128132

15. Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009; 39 (4): 432 - 438. https://doi.org/10.1002/mus.21206

16. A, Cocito D, Bottacchi E, et al.; PARCIDP. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol NeurosurgPsychiatry. 2007; 78 (12): 1349 - 1353. https://doi.org/10.1136/jnnp.2007.114868

17. M, Potulska-Chromik A, Lipowska M, et al. Pediatric CIDP: Diagnosis and Management. A Single-Center Experience. Front Neurol. 2021; 12: 667378. https://doi.org/10.3389/fneur.2021.667378

18. Uzan G, Vural A, D, et al. Pediatric-Onset Chronic Inflammatory Demyelinating Polyneuropathy: A Multicenter Study. Pediatr Neurol. 2023; 145: 3 - 10. https://doi.org/10.1016/j.pediatrneurol.2023.04.018

19. McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol. 1999; 46 (6): 910 - 913. https://doi.org/10.1002/1531-8249(199912)46:6%3C910::AID-ANA14%3E3.0.CO;2-2

20. Sotgiu S, Onida I, Magli G, et al. Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy. Neuropediatrics. 2021; 52 (1): 56 - 61. https://doi.org/10.1055/s-0040-1715626

21. Majumdar A, Hartley L, Manzur AY, et al. A case of severe congenital chronic inflammatory demyelinating polyneuropathy with complete spontaneous remission. Neuromuscul Disord. 2004; 14 (12): 818 - 821. https://doi.org/10.1016/j.nmd.2004.0 9.003

22. Silwal A, Pitt M, Phadke R, et al. Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neuromuscul Disord. 2018; 28: 757 - 765. https://doi.org/10.1016/j.nmd.2018.06.001

23. Dalakas M.C., Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP//Nat. Rev. Neurol. 2011. Vol. 7. P. 507 - 517. https://doi.org/10.1038/nrneurol.2011.121

24. Markowitz J.A., Jeste S.S., Kang P.B. Child neurology: chronic inflammatory demyelinating polyradiculoneuropathy in children. Neurology. 2008; 71: e74 - e78. https://doi.org/10.1212/01.wnl.0000336646.91734.b1

25. Козырева А.А., Бембеева Р.Ц, Дружинина Е.С., Заваденко Н.Н., Колпакчи Л.М, Пилия С.В. Современные аспекты диагностики и лечения хронической воспалительной демиелинизирующей полинейропатии у детей. Журнал неврологии и психиатрии им. С.С. Корсакова 2024, т. 124, No 2, с. 58 - 68 https://doi.org/10.17116/jnevro202412402158

26. Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south East England. J Neurol Neurosurg Psychiatry. 1999; 66 (5): 677 - 680. https://doi.org/10.1136/jnnp.66.5.677

27. Costello F, Lee AG, Afifi AK, Kelkar P, Kardon RH, White M. Childhoodonset chronic inflammatory demyelinating polyradiculoneuropathy with cranial nerve involvement. J Child Neurol. (2002) 17: 819 - 23. https://doi.org/10.1177/088307380201701112

28. Riekhoff AG, Jadoul C, Mercelis R, Cras P, Ceulemans BP. Childhood chronic inflammatory demyelinating polyneuroradiculopathy-three cases and a review of the literature. Eur J Paediatr Neurol. (2012) 16: 315 - 31. https://doi.org/10.1016/j.ejpn.2011.12.003

29. Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 2019; 18:784. https://doi.org/10.1016/s1474-4422(19) 30144-9

30. Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 2019; 90: 125. doi: 10.1136/jnnp-2018-318714

31. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve. 1997; 20: 1569 - 1575. doi: 10.1002/(sici)1097-4598(199712)20:12<1569::aid-mus12>3.0.co;2-w.

32. Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001; 184: 57 - 63. https://doi.org/10.1016/s0022-510x(00)00493-7

33. Stojkovic T, de Seze J, Hurtevent JF, Fourrier F, Vermersch P. Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2003; 27: 497 - 499. https://doi.org/10.1002/mus.10361

34. Henderson RD, Sandroni P, Wijdicks EF. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol. 2005; 252: 1235 - 1237. https://doi.org/10.1007/s00415-005-0848-2

35. Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology. 1998; 50: 1179 - 1182. https://doi.org/10.1212/wnl.50.4.1179

36. Yamamoto K, Watarai M, Hashimoto T, Ikeda S. Chronic inflammatory demyelinating polyradiculoneuropathy with autonomic involvement. Muscle Nerve. 2005; 31: 108 - 112. https://doi.org/10.1002/mus.20140

37. Boukhris S, Magy L, Li Y, Debras C, Vallat JM. Autonomic nervous system involvement in chronic inflammatory demyelinating polyneuropathy. Rev Neurol (Paris). 2005; 161: 1228 - 1231. doi: 10.1016/s0035-3787(05)85198-7.

38. Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from syndrome with treatment related fluctuations. Neurology. 2005; 65: 138 - 140. https://doi.org/10.1212/01.wnl.0000167549.09664.b8

39. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating syndrome. Neurology. 2010; 74: 1680 - 1686. https://doi.org/10.1212/wnl.0b013e3181e07d14

40. Vinit Suri, Shishir Pandey, Jyoti Singh, Amarnath Jena. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination. BMJ Case Rep. 2021; 14 (10): e245816. https://doi.org/10.1136%2Fbcr-2021-245816

41. Sudeep KC, Bansal A, Randhawa MS, et al. Recurrent Guillain-Barre syndrome: clinical profile and outcome. Indian J Pediatr. 2023. https://doi.org/10.1007/s12098-023-04746-y.

42. Kuitwaard K, Van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2009; 80: 56 - 9

43. Verma A, Tandan R, Adesina AM, Pendlebury WW, Fries TJ, Bradley WG. Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. Acta Neurol Scand. 1990; 81: 516 - 521. https://doi.org/10.1111/j.1600-0404.1990.tb01011.x

44. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory. doi: 10.1111/j.1529-8027.2010.00251.x.

45. Rotta FT, Sussman AT, Bradley WG, Ram Ayyar D, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2000; 173 (2): 129 - 139. 89. https://doi.org/10.1016/s0022-510x(99)00317-2

46. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000; 54 (3): 615 - 620. https://doi.org/10.1212/wnl.54.3.615

47. Larue S, Bombelli F, Viala K, et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol. 2011; 18: 899 - 905. https://doi.org/10.1111/j.1468-1331.2010.03312.x

48. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelinassociated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016; 10: CD002827. https://doi.org/10.1002/14651858.cd002827.pub4

49. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982; 32: 958 - 964. https://doi.org/10.1212/wnl.32.9.958

50. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve. 1999; 22: 560 - 566. https://doi.org/10.1002/(sici)1097-4598(199905)22:5%3C560::aid-mus2%3E3.0.co;2-q

51. van den Berg-Vos RM, van den Berg LH, Franssen H, et al. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology. 2000; 54: 26 - 32. https://doi.org/10.1212/wnl.54.1.26

52. Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating neuropathy. Brain. 1996; 119: 765 - 774. https://doi.org/10.1093/brain/119.3.765

53. Van den Bergh PY, Thonnard JL, Duprez T, Laterre EC. Chronic demyelinating hypertrophic brachial plexus neuropathy. Muscle Nerve. 2000; 23: 283 - 288. https://doi.org/10.1002/(sici)1097-4598(200002)23:2%3C283::aid-mus23%3E3.0.co;2-q

54. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994; 57: 778 - 783. https://doi.org/10.1136/jnnp.57.7.778

55. Sabatelli M, Madia F, Mignogna T, Lippi L, Quaranta L, Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001; 248: 772 - 777. https://doi.org/10.1007/s004150170093

56. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst. 2010; 15: 295 - 301. https://doi.org/10.1111/j.1529-8027.2010.00290.x

57. Pegati A, Boisseau W, Maisonobe T, et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treatment. J Peripher Nerv Syst. 2020; 25: 162 - 170. https://doi.org/10.1111/jns.12380

58. Eftimov F, Liesdek MH, Verhamme C, van Schaik IN, PREDICT Study Group. Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol. 2014; 14: 72. https://doi.org/10.1186/1471-2377-14-72

59. Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992; 55: 677 - 680. https://doi.org/10.1136/jnnp.55.8.677

60. Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an underrecognized entity? Muscle Nerve. 2013; 48: 727 - 732. https://doi.org/10.1002/mus.23821

61. Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathy". Muscle Nerve. 1995; 8: 440 - 444. https://doi.org/10.1002/mus.880180411

62. Thonnard JL, Detrembleur C, Van den Bergh PYK. Assessment of hand function in a patient with chronic sensory demyelinating neuropathy. Neurology. 1997; 49: 253 - 257. https://doi.org/10.1212/wnl.49.1.253

63. van Dijk GW, Notermans NC, Franssen H, Wokke JH. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a longterm follow-up study. J Neurol. 1999; 246: 1134 - 1139. https://doi.org/10.1007/s004150050531

64. Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculoneuropathy: a possibly treatable sensory ataxia. Neurology. 2004; 63: 1662 - 1669. https://doi.org/10.1212/01.wnl.0000142507.12763.58

65. Rajabally YA, Wong SL. Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology. J Clin Neuromuscul Dis. 2012; 13: 149 - 152. doi: 10.1097/CND.0b013e31822484fb.

66. Clerici AM, Nobile-Orazio E, Mauri M, Squellati FS, Bono GG. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a longlasting case of chronic immune sensory polyradiculopathy. BMC Neurol. 2017; 17: 127. https://doi.org/10.1186/s12883-017-0906-2

67. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst. 2010; 15: 1 - 9. https://doi.org/10.1111/j.1529-8027.2010.00245.x

68. Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010; 17: 356 - 363. doi: 10.1111/j.1468-1331.2009.02930

69. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013; 73: 370 - 380. https://doi.org/10.1002/ana.23794

70. Doppler K, Appeltshauser L, Wilhelmi K, et al. Destruction of para-nodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry. 2015; 86: 720 - 728. https://doi.org/10.1136/jnnp-2014-309916

71. Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain. 2015; 138: 1484 - 1491. https://doi.org/10.1093/brain/awv054

72. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014; 82: 879 - 886. https://doi.org/10.1212/wnl.0000000000000205

73. Ogata H, Yamasaki R, Hiwatashi A, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015; 2: 960 - 971. https://doi.org/10.1002/acn3.248

74. Devaux JJ, Miura Y, Fukami Y, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016; 86: 800 - 807. https://doi.org/10.1212/wnl.0000000000002418

75. Cortese A, Lombardi R, Briani C, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2020; 7: e639. doi: 10.1212/NXI.0000000000000639.

76. E, Fehmi J, C, et al. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyneuropathy. Brain. 2021; 144: 1183 - 1196. doi: 10.1093/brain/awab014.

77. Delmont E, Manso C, Querol L, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 2017; 140: 1851 - 1858. https://doi.org/10.1093/brain/awx124

78. Stengel H, Vural A, Brunder A-M, et al. Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm. 2019; 6: e603. doi: 10.1212/NXI.0000000000000603.

79. Vallat JM, Yuki N, Sekiguchi K, et al. Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with antineurofascin 155 antibodies. Neuromuscul Disord. 2017; 27: 290 - 293. https://doi.org/10.1016/j.nmd.2016.10.008

80. Koike H, Nishi R, Ikeda S, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology. 2018; 4: 1051 - 1060. https://doi.org/10.1212/wnl.0000000000006625

81. Querol L, Rojas-Garcia R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015; 2: e149. doi: 10.1212/NXI.0000000000000149.

82. Nobile-Orazio E, Gallia F, Judica E. Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders. In: Katirji B, Kaminsky HJ, Ruff RL, eds. Neuromuscular Disorders in Clinical Practice. 2nd ed. New York, NY: Springer; 2014: 612 - 614.

83. Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019; 24 (suppl 2): S74 - S85. https://doi.org/10.1111/jns.12339

84. Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019; 24 (suppl 2): S52 - S62. https://doi.org/10.1111/jns.12338

85. Van Nes, S.I. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies/S.I. Van Nes, E.K. Vanhoutte, P.A. van Doorn et al.//Neurology. - Vol. 76, N 4. - P. 337 - 345 https://doi.org/10.1212/wnl.0b013e318208824b

86. Hughes, R. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy/R. Hughes, S. Bensa, H. Willison//Annals of Neurology. - 2001. - Vol. 50, N 2. - P. 195 - 201 https://doi.org/10.1002/ana.1088

87. Супонева Н.А., Арестова А.С., Мельник Е.А., Зимин А.А., Зайцев А.Б., Якубу А., Щербакова Е.С., Юсупова Д.Г., Гришина Д.А., Гнедовская Е.В., Пирадов М.А. Нервно-мышечные болезни. 2023; 13 (1): 68 - 74. https://doi.org/10.17650/2222-8721-2023-13-168-74

88. Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005; 10: 158 - 173. https://doi.org/10.1111/j.1085-9489.2005.0010206.x

89. Dyck, P.J. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry/P.J. Dyck, W.R. Sherman, L.M. Hallcher et al.//Ann Neurol. - 1980. - Vol. 8, N 6. - P. 590 - 596. Валидация Шкалы оценки степени невропатических нарушений NIS выполнена на базе ФГБНУ НЦН (https://neurology.ru/o-centre/struktura/institut-neyroreabilitatsii-i-vosstanovitelnykh-tekhnologiy/gruppa validatsii-mezhdunarodnykh-shkal-i-oprosnikov/). https://neurology.ru/upload/medialibrary/52b/1bgw9fwrkrvi8ppmpw73jnepb2z4gsj0/SHkala-otsenki-stepeni-nevropaticheskikh-narusheniy-NIS.pdf

90. Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical sig-nificance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010; 81: 1194 - 1199. https://doi.org/10.1136/jnnp.2009.194324

91. Vanhoutte EK, Latov N, Deng C, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG - the ICE study. Eur J Neurol. 2013; 20: 748 - 755. https://doi.org/10.1111/j.1468-1331.2012.03851.x

92. Doneddu PE, Mandia D, Gentile F, et al. Home monitoring of main-tenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020; 25: 238 - 246. https://doi.org/10.1111/jns.12396

93. Allen JA, Pasnoor M, Dimachkie MM, et al. Quantifying treatment-related fluctuations in CIDP: results of the GRIPPER study. Neurology. 2021; 96: e1876 - e1886 https://doi.org/10.1212/wnl.0000000000011703

94. Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005; 10: 158 - 173. doi: 10.1111/j.1085-9489.2005.0010206.x.

95. Vanhoutte EK, Latov N, Deng C, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG - the ICE study. Eur J Neurol. 2013; 20: 748 - 755. https://doi.org/10.1111/j.1468-1331.2012.03851.x

96. Doneddu PE, Mandia D, Gentile F, et al. Home monitoring of main-tenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020; 25: 238 - 246. https://doi.org/10.1111/jns.12396

97. Chhabra A, Carrino JA, Farahani SJ, Thawait GK, Sumner CJ, Wadhwa V, Chaudhary V, Lloyd TE. Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging. 2016 Dec; 44 (6): 1513 - 1521. doi: 10.1002/jmri.25293. Epub 2016 Apr 29. PMID: 27126998.

98. Zaidman C.M., Harms M.B., Pestronk A. Ultrasound of inherited vs. acquired demyelinating polyneuropathies. Neurol 2013; 260 (12): 3115 - 21. DOI: 10.1007/s00415-013-7123-8. PMID: 24101129. https://doi.org/10.1007/s00415-013-7123-8

99. Sugimoto T., Ochi K., Hosomi N., Matsumoto M. Ultrasonographic diagnosis of inflammatory neuropathies. Brain Nerve 2014; 66 (3): 223 - 8. PMID: 24607946.

100. Наумова Е.С. Клинико-сонографическое исследование периферических нервов при дизиммунных и наследственных полинейропатиях. Автореферат дис. кандидата медицинских наук: 14.01.11., 2018

101. Chhabra A, Carrino JA, Farahani SJ, Thawait GK, Sumner CJ, Wadhwa V, Chaudhary V, Lloyd TE. Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging. 2016 Dec; 44 (6): 1513 - 1521. doi: 10.1002/jmri.25293. Epub 2016 Apr 29. PMID: 27126998.

102. Sommer CL, Brandner S, Dyck PJ, et al. Peripheral Nerve Society guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst. 2010; 15: 164 - 175. https://doi.org/10.1111/j.1529-8027.2010.00276.x

103. Garces-Sanchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck PJ. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus neuropathy? Ann Neurol. 2011; 69: 1043 - 1054. https://doi.org/10.1002/ana.22334

104. Xu M, Pinto M, Sun C, et al. Expanded teased nerve fibre pathological conditions in disease association. J Neurol Neurosurg Psychiatry. 2019; 90: 138 - 140. https://doi.org/10.1136/jnnp-2018-319077

105. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005; 65: 1924 - 1929. https://doi.org/10.1212/01.wnl.0000188879.19900.b7

106. Vallat JM, Tabaraud F, Magy L, et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve. 2003; 27: 478 - 485. https://doi.org/10.1002/mus.10348

107. Dalakas M.C., Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP//Nat. Rev. Neurol. 2011. Vol. 7. P. 507 - 517.

108. Lehmann H.C., Burke D., Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment Journal of Neurology, Neurosurgery & Psychiatry 2019; 90: 981 - 987

109. Куренков А.Л., Никитин С.С., Бурсагова Б.И., Кузенкова Л.М. Особенности хронической воспалительной демиелинизирующей полиневропатии у детей. Журнал "Нервно-мышечные болезни". 2012. N 2. С. 40 - 51.

110. Никитин С.С., Куренков А.Л. Особенности острой воспалительной и хронической демиелинизирующих невропатий у детей. В книге: Аутоиммунные заболевания в неврологии (под ред. И.А. Завалишина, М.А. Пирадова, А.Н. Бойко, С.С. Никитина, Н.Н. Спирина, А.В. Переседовой). Клиническое руководство. - Т. 2. - М.: РООИ "Здоровье человека", 2014. - С. 63 - 75.

111. Куренков А.Л., Бурсагова Б.И., Кузенкова Л.М., Пак Л.А., Увакина Е.В. Хроническая воспалительная демиелинизирующая полинейропатия в детском возрасте: критерии диагноза и подходы к патогенетическому лечению. Фарматека. 2019. Т. 26. N 10. С. 21 - 26.

112. Ghaemi N., Hasanabadi H., Ashrafzadeh F., Sarvari S., Rahimi H., Hashemian S. Peripheral Neuropathy in Children and Adolescents with Insulin-dependent Diabetes Mellitus. Iran J Child Neurol. 2018 Spring; 12 (2): 83 - 90

113. Gorson K.C. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012; 5 (6): 359 - 373.

114. Azathioprine: Drug information (https://www.uptodate.com/contents/azathioprine-drug-information?topicRef=5265&source=see_link(

115. Cyclosporine (ciclosporin) (systemic): Drug information (https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information?topicRef=9217&source=see_link#F8012602)

116. Elena E Perez, MD, PhDNadine Shehata, MD, MSc, FRCPC Section Editor:Jordan S Orange, PhDDeputy Editors:Jennifer S Tirnauer, Anna M Feldweg, Intravenous immune globulin: Adverse effects (https://www.uptodate.com/contents/intravenous-immune-globulin-adverse-effects?topicRef=5265&source=see_link)

117. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005 Dec; 29 (3): 173 - 84

118. Rajabally Y.A., Varanasi S. Practical electrodiagnostic value of F-wave studies in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2013; 124 (1): 171 - 175.

119. Nevo Y, Topaloglu H. 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8 - 10, 2000. Neuromuscul Disord. 2002 Feb; 12(2): 195 - 200

120. McMillan HJ, Kang PB, Jones HR, Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul Disord. 2013; 23: 103 - 111. https://doi.org/10.1016/j.nmd.2012.09.008

121. G, D, CM, et al. Challenges in pediatric chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2016; 26 (12): 817 - 824. https://doi.org/10.1016/j.nmd.2016.09.016

122. Yang L. The diagnostic value of MRI in pediatric chronic inflammatory demyelinating polyradiculoneuropathy. Brain Dev. 2016; 38: 173. https://doi.org/10.1016/j.braindev.2015.04.011

123. Parikh S., Bernard G., Leventer R.J., van der Knaap M.S., van Hove J., Pizzino A., McNeill N.H., Helman G., Simons C., Schmidt J.L., Rizzo W.B., Patterson M.C., Taft R.J., Vanderver A.; GLIA Consortium. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015 Apr; 114 (4): 501 - 515

124. Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom. 2004 Winter; 7 (4): 359 - 63.

125. Laura K. Bachrach, Catherine M. Gordon et al. Bone Densitometry in Children and Adolescents. Pediatrics October 2016, 138 (4) e20162398

126. McMillan H.J., Kang P.B., Jones H.R., Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul Disord. 2013; 23 (2): 103 - 111.

127. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010 Mar; 17 (3): 356 - 63.

128. Mori M, Kuwabara S, Nemoto Y, Tamura N, Hattori T. Concomitant chronic inflammatory demyelinating polyneuropathy and myasthenia gravis following cytomegalovirus infection. J Neurol Sci. 2006 Jan 15; 240 (1 - 2): 103 - 6.

129. Richard A Lewis, Suraj Ashok Muley, Section Editor: Jeremy M Shefner, PhDDeputy Editor:Richard P Goddeau, Jr, DO, FAHChronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis A (https://www.uptodate.com/contents/chronic-inflammatory-demyelinating-polyneuropathy-etiology-clinical-features-and-diagnosis?source=history_widget#H3648072611)

130. Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol. 1986 Feb; 14 (2 Pt 1): 161 - 77.

131. Dyck PJ, O"Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982 Feb; 11 (2): 136 - 41.

132. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Mar; 9 (3): 245 - 53.

133. Куренков А.Л., Бурсагова Б.И., Подклетнова Т.В., Абдуллаева Л.М. Хроническая воспалительная демиелинизирующая полиневропатия у детей: современные критерии установления диагноза и патогенетическое лечение. Неврологический журнал имени Л.О. Бадаляна. 2022; 3 (2): 72 - 81. https://doi.org/10.46563/2686-8997-2022-3-2-72-81

134. Sladky J.T. What is the best initial treatment for childhood chronic inflammatory demyelinating polyneuropathy: corticosteroids or intravenous immunoglobulin. Muscle Nerve. 2008; 38: 1638 - 1643

135. Eftimov F., Winer J.B., Vermeulen M, de Haan R, van Schaik I.N. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013 Dec 30; 12: CD001797

136. Oaklander A.L., Lunn M.P., Hughes R.A., van Schaik I.N., Frost C., Chalk C.H.. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017; 1 (1): CD010369. Published 2017 Jan 13.

137. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994; 36: 838 - 845. https://doi.org/10.1002/ana.410360607

138. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013; (12): CD001797. https://doi.org/10.1002/14651858.CD001797.pub3.

139. Cianci P. et al. Subcutaneous immunoglobulin in infantile chronic inflammatory demyelinating polyneuropathy: A case report//Journal of Pediatric Neurosciences. - 2019. - Т. 14. - N. 1. - С. 38 - 41.MLA

140. van Schaik IN, Mielke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019; 6: e590. https://doi.org/10.1212/nxi.0000000000000590

141. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013; 20: 836 - 842 doi: 10.1111/ene.12080.

142. Markvardsen LH, Sindrup SH, Christiansen I, et al. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol. 2017; 24: 412 - 418. https://doi.org/10.1111/ene.13218

143. Matsubayashi Tomo et al (2022) Experience with the use of subcutaneous immunoglobulin preparations for chronic inflammatory demyelinating polyneuritis in children. Brain Dev 54 (2): 132 - 134. https://doi.org/10.11251/ojjscn.54.132

144. Hughes R.A., Mehndiratta M.M., Rajabally Y.A. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017; 11(11): CD002062. Published 2017 Nov 29. doi:10.1002/14651858.CD002062.pub4

145. Doneddu PE, Cocito D, Manganelli F, et al. Italian CIDP Database study group. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019; 90: 125 - 132. https://doi.org/10.1136/jnnp-2018-318714

146. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994; 57: 778 - 783. https://doi.org/10.1136/jnnp.57.7.778

147. Pegat A, Boisseau W, Maisonobe T, et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treatment. J Peripher Nerv Syst. 2020; 25: 162 - 170. https://doi.org/10.1111/jns.12380

148. Eftimov F, Liesdek MH, Verhamme C, van Schaik IN, PREDICT Study Group. Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol. 2014; 14: 72. https://doi.org/10.1186/1471-2377-14-72.

149. Rafai MA, Boulaajaj FZ, Sekkat Z, El Moutawakkil B, Slassi I. Place des bolus de dans le traitement des chroniques de l"enfant [Methylprednisolone pulse in treatment of childhood chronic inflammatory demyelinating polyneuropathy]. Arch Pediatr. 2010 Sep; 17 (9): 1293 - 9. French. doi: 10.1016/j.arcped.2010.06.022

150. Rafai MA, Moutaouakil F, El Otmani H, Fadel H, Boulaajaj FZ, El Moutawakil B, Gam I, Slassi I. chronique idiopathique de l"enfant: sous bolus de [Chronic inflammatory demyelinating polyradiculoneuropathy in childhood: outcomes after methylprednisolone pulse therapy]. Rev Neurol (Paris). 2006 Jun; 162 (6 - 7): 753 - 6. French. doi: 10.1016/s0035-3787(06)75075-5

151. Куренков А.Л., Кузенкова Л.М., Никитин С.С., Бурсагова Б.И. Хроническая воспалительная демиелинизирующая полиневропатия у детей: диагностика и лечение. Вопросы современной педиатрии. 2014. Том 13. N 5. - С. 34 - 41

152. Chang SJ, Lee JH, Kim SH, Lee JS, Kim HD, Kang JW, Lee YM, Kang HC. Chronic inflammatory demyelinating polyneuropathy in children: a report of four patients with variable relapsing courses. Korean J Pediatr. 2015 May; 58 (5): 194 - 8. doi: 10.3345/kjp.2015.58.5.194

153. Mehndiratta M.M., Hughes R.A., Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015; 2015 (8): CD003906. Published 2015 Aug 25.

154. Dyck PJ, Daube J, O"Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986; 314: 461 - 465. https://doi.org/10.1056/nejm198602203140801

155. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996; 119: 1055 - 1066. https://doi.org/10.1093/brain/119.4.1055

156. Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015; 2015(8): CD003906. https://doi.org/10.1002/14651858.cd003906.pub4

157. Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016; 54: 2 - 15. https://doi.org/10.1016/j.transci.2016.01.003

158. Mahdi-Rogers M., Brassington R., Gunn A.A., van Doorn P.A., Hughes R.A. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017; 5 (5): CD003280. Published 2017 May 8

159. Шевченко А.В. Хронические воспалительные демиелинизирующие полиневропатии у детей (клиника, диагностика, дифференциальная диагностика): дис. - Российский Государственный Медицинский Университет, 2007.

160. Bansal V.K., Meriggioli M.N. Immunotherapy in the treatment autoimmune neuromuscular disease. In book: Neuromuscular disorders in clinical practice (Eds. B. Katirji, H.J. Kaminski, R.L. Ruff). - New York: Springer, 2014. - P. 341 - 362.

161. Козырева А.А., Бембеева Р.Ц., Дружинина Е.С., Заваденко Н.Н., Колпакчи Л.М., Пилия С.В. Современные аспекты диагностики и лечения хронической воспалительной демиелинизирующей полинейропатии у детей. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024; 124 (2): 58 - 68. https://doi.org/10.17116/jnevro202412402158

162. Kyllerman M, Risberg K, Beckung E. Chronic inflammatory demyelinating polyneuropathy in children: follow-up investigation and results of prednisone-azathioprine treatment. Eur J PaediatrNeurol. (1999) 3: 209 - 15. doi: 10.1016/S1090-3798(99)90083

163. Rostasy KM, Diepold K, Buckard J, Brockmann K, Wilken B, Hanefeld F. Progressive muscle weakness after high-dose steroids in two children with CIDP. Pediatr Neurol. 2003 Sep; 29 (3): 236 - 8. doi: 10.1016/s0887-8994(03)00222-4

164. Visudtibhan A, Chiemchanya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol. 2005 Nov; 33 (5): 368 - 72. doi: 10.1016/j.pediatrneurol.2005.05.015

165. Y., Vatti N., C., Chang C., O., Gershwin M.E., Anaya J.M. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019 Aug; 102: 8 - 37

166. Хайбуллин Т.И., Хабиров Ф.А., Аверьянова Л.А., Ахмедова Г.М., Бабичева Н.Н., Гранатов Е.В. Хроническая воспалительная демиелинизирующая полирадикулоневропатия и патогенетически близкие синдромы: диагностика и лечение Практическая медицина. 2014. N 2 (78): 21 - 30. http://pmarchive.ru/xronicheskaya-vospalitelnaya-demieliniziruyushhaya-poliradikulonevropatiya-i-patogeneticheski-blizkie-sindromy-diagnostika-i-lechenie/

167. Гапешин Р.А., Баранцевич Е.Р., Руденко Д.И., и др. Современные представления о лечении хронической воспалительной демиелинизирующей полинейропатии (обзор литературы)//Ученые записки СПбГМУ им. И. П. Павлова. 2019. N 1.

168. Stevens, J. A. E., Llewelyn, G., & Hartley, L. Rituximab as an adjunct to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Paediatric Neurology, 21, e114. doi: 10.1016/j.ejpn.2017.04.957

169. Mara L. Becker, Dan Lovell, Steven J. Leeder, Chapter 12 - Pharmacology and Drug Therapy: Nonbiologic Therapies, Editor(s): Ross E. Petty, Ronald M. Laxer, Carol B. Lindsley, Lucy R. Wedderburn, Textbook of Pediatric Rheumatology (Seventh Edition), W.B. Saunders, 2016, Pages 140 - 160.e16, ISBN 9780323241458, https://doi.org/10.1016/B978-0-323-24145-8.00012-0.

170. MC, Finley GA. Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence. Pain Res Manag. 2013 Jan - Feb; 18 (1): 47 - 50. doi: 10.1155/2013/402863. PMID: 23457686; (https://www.sciencedirect.com/science/article/pii/B9780323241458000120)

171. de Leeuw TG, der Zanden TV, Ravera S, Felisi M, Bonifazi D, Tibboel D, Ceci A, Kaguelidou F, de Wildt SN, On Behalf Of The Gapp Consortium. Diagnosis and Treatment of Chronic Neuropathic and Mixed Pain in Children and Adolescents: Results of a Survey Study amongst Practitioners. Children (Basel). 2020 Nov 2; 7 (11): 208. doi: 10.3390/children7110208. PMID: 33147808; PMCID: PMC7694093

172. Garssen MP, Bussmann JB, Schmitz PI et al. Physical training and fatigue, fitness and quality of life in Guillain-Barre syndrome and CIDP. Neurology. 2004; 63 (12): 2393 - 2395

173. Graham RC, Hughes RA, White CM. A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. J. Neurol. 2007; 254 (2): 228 - 235

174. Markvardsen L. H., Overgaard, K., Heje, K., Sindrup, S. H., Christiansen, I., Vissing, J., & Andersen, H. Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. Muscle & Nerve. 2018; 57 (1): 70 - 76

175. Markvardsen LK, Carstens AR, Knak KL, Overgaard K, Vissing J, Andersen H. Muscle strength and aerobic capacity in patients with CIDP one year after participation in an exercise trial. J Neuromuscul Dis. 2019; 6 (1): 93 - 97. doi: 10.3233/JND-180344

176. Janssen J, Bunce M, Nixon J, Dunbar M, Jones S, Benstead J et al. A clinical case series investigating the effectiveness of an exercise intervention in chronic inflammatory demyelinating polyneuropathy. Physiotherapy Practice and Research. 2018; 39 (1): 37 - 44

177. Селицкий М.М. Современные методы диагностики хронической воспалительной демиелинизирующей полиневропатии. Научно-практический терапевтический журнал. 4 (44). 2015. 36 - 42.

178. Doneddu PE, Bianchi E, Cocito D, Manganelli F, Fazio R, Filosto M, Mazzeo A, Cosentino G, Cortese A, Jann S, Clerici AM, Antonini G, Siciliano G, Luigetti M, Marfia GA, Briani C, Lauria G, Rosso T, Cavaletti G, Carpo M, Benedetti L, Beghi E, Liberatore G, Santoro L, Peci E, Tronci S, Cotti Piccinelli S, Toscano A, Piccolo L, Verrengia EP, Leonardi L, Schirinzi E, Mataluni G, Ruiz M, Dacci P, Nobile-Orazio E; Italian CIDP Database Study Group. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. Eur J Neurol. 2020 Jan; 27(1): 136 - 143. doi: 10.1111/ene.14044

179. Вакцинопрофилактика "Медицинские противопоказания к проведению профилактических прививок препаратами национального календаря прививок" (утв. Главным государственным санитарным врачом РФ от 9 января 2002 г.)

180. Kuitwaard K., Bos-Eyssen M.E., Blomkwist-Markens P.H., van Doorn P.A. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009; 14 (4): 310 - 315